Bodart V, Rainey W E, Fournier A, Ong H, De Léan A
Department of Pharmacology, Faculty of Medicine, Université de Montréal, Québec, Canada.
Mol Cell Endocrinol. 1996 Apr 19;118(1-2):137-44. doi: 10.1016/0303-7207(96)03776-8.
The inhibitory effect of atrial natriuretic peptide (ANP) on angiotensin II (AII)-stimulated aldosterone secretion has been previously studied in rat and bovine adrenal zona glomerulosa cells in primary culture. However the understanding of the mode of action of ANP at the molecular level has been hampered by limitations of those primary cell culture systems and by the lack of cell lines from human adrenal cortex. Here we demonstrate the presence of fully functional ANP receptors in the recently characterized AII-responsive adrenocortical carcinoma cell line H295R. Specific saturable binding of 125I-rANP to H295R cell membrane preparations revealed a single class of high affinity binding sites with a density of 20 fmol/mg of protein. The pharmacological profile of this ANP receptor was documented by competitive binding of 125I-rANP with naturally occurring natriuretic peptides. rANP was the most potent with a Kd of 42 pM. pBNP32 was less potent with a Kd of 174 pM. 125I-rANP binding was not competed by pCNP (NPRB-specific ligand) nor by C-ANF (NPRC-specific ligand). Photoaffinity labeling of membrane preparations with 125I-BPA-ANP revealed a single specific protein of molecular weight around 130 kDa. This protein was further identified by immunodetection with a specific antibody directed to the human ANP-specific receptor NPRA. Natriuretic peptides stimulated cGMP production by the receptor-coupled guanylate cyclase with the same specificity. Aldosterone production by AII-stimulated H295R cells was dose-dependently inhibited by rANP with an ED50 of 1.5 nM. In addition, we used this model to test two chimeric analogs of ANP and BNP. pBNP1 and pBNP3 were, respectively, 4- and 2-fold more potent than rANP in competing for 125I-rANP binding with Kd of 10 and 20 pM. pBNP1 was 24-fold more potent in inhibiting AII-stimulated aldosterone production with ED50 of 63 pM. pBNP1 is therefore the most potent natriuretic peptide analog tested. In summary, the human H295R cell line contains NPRA receptors positively coupled to the particulate guanylate cyclase and that antagonize angiotensin II stimulation of aldosterone secretion.
心房利钠肽(ANP)对血管紧张素II(AII)刺激的醛固酮分泌的抑制作用,此前已在原代培养的大鼠和牛肾上腺球状带细胞中进行过研究。然而,由于这些原代细胞培养系统的局限性以及缺乏来自人类肾上腺皮质的细胞系,对ANP在分子水平上的作用模式的理解受到了阻碍。在此,我们证明了在最近鉴定的AII反应性肾上腺皮质癌细胞系H295R中存在功能完全正常的ANP受体。125I-rANP与H295R细胞膜制剂的特异性饱和结合显示出一类单一的高亲和力结合位点,蛋白质密度为20 fmol/mg。通过125I-rANP与天然存在的利钠肽的竞争性结合,记录了该ANP受体的药理学特征。rANP的效力最强,Kd为42 pM。pBNP32的效力较弱,Kd为174 pM。125I-rANP的结合不受pCNP(NPRB特异性配体)或C-ANF(NPRC特异性配体)的竞争。用125I-BPA-ANP对膜制剂进行光亲和标记,显示出一种分子量约为130 kDa的单一特异性蛋白质。用针对人ANP特异性受体NPRA的特异性抗体通过免疫检测进一步鉴定了该蛋白质。利钠肽以相同的特异性刺激受体偶联的鸟苷酸环化酶产生cGMP。rANP以剂量依赖性方式抑制AII刺激的H295R细胞产生醛固酮,ED50为1.5 nM。此外,我们使用该模型测试了两种ANP和BNP的嵌合类似物。在竞争125I-rANP结合方面,pBNP1和pBNP3的效力分别比rANP高4倍和2倍,Kd分别为10和20 pM。在抑制AII刺激的醛固酮产生方面,pBNP1的效力高24倍,ED50为63 pM。因此,pBNP1是所测试的最有效的利钠肽类似物。总之,人H295R细胞系含有与颗粒性鸟苷酸环化酶正偶联的NPRA受体,该受体拮抗血管紧张素II对醛固酮分泌的刺激作用。